A cross-study transcriptional analysis of Parkinson's disease

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Sutherland, Greg T ^a   Matigian, Nicholas A ^a   Chalk, Alistair M ^a   Anderson, Matthew J ^a   Silburn, Peter A ^a,b   Mackay Sim, Alan ^a   Wells, Christine A ^a   Mellick, George D ^a,c,d  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; SOMATOMEDIN C; DOPAMINE; SIGNAL PEPTIDE;

ARTICLE; AUTOPSY; BRAIN TISSUE; CASE CONTROL STUDY; CASE STUDY; CELL LOSS; CONTROLLED STUDY; CYTOARCHITECTURE; DOPAMINERGIC NERVE CELL; DOWN REGULATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROPATHOLOGY; PARKINSON DISEASE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MICROARRAY ANALYSIS; NERVE CELL; PATHOLOGY;

DOPAMINE; GENE EXPRESSION PROFILING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROARRAY ANALYSIS; NEURONS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 63349091122     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004955     Document Type: Article

References (51)

1. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56: 33-39.
2. Hughes AJ (1997) Clinicopathological aspects of Parkinson's disease. Eur Neurol 38 Suppl 2: 13-20.
3. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
4. Comella CL (2007) Sleep disorders in Parkinson's disease: an overview. Mov Disord 22 Suppl 17: S367-373.
5. Dubow JS (2007) Autonomic dysfunction in Parkinson's disease. Dis Mon 53: 265-274.
6. Hawkes C (2006) Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol 63: 133-151.
7. Ziemssen T, Reichmann H (2007) Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 13: 323-332.
8. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
9. Braak H, Muller CM, Rub U, Ackermann H, Bratzke H, et al. (2006) Pathology associated with sporadic Parkinson's disease-where does it end? J Neural Transm Suppl. pp 89-97.
10. Hubbard PS, Esiri MM, Reading M, McShane R, Nagy Z (2007) Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat 211: 117-124.
11. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol 116: 125-128.
12. Bossers K, Meerhoff G, Balesar R, van Dongen JW, Kruse CG, et al. (2008) Analysis of Gene Expression in Parkinson's Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death. Brain Pathol.
13. Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B, Asteris G, Clark TW, et al. (2007) Effects of gender on nigral gene expression and parkinson disease. Neurobiol Dis 26: 606-614.
14. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, et al. (2006) Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 7: 1-11.
15. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, et al. (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111: 1543-1573.
16. Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, et al. (2005) Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol 62: 917-921.
17. Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, et al. (2006) Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol Dis 21: 305-313.
18. Papapetropoulos S, Ffrench-Mullen J, McCorquodale D, Qin Y, Pablo J, et al. (2006) Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease. Gene Expr 13: 205-215.
19. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, et al. (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 104: 955-960.
20. Vogt IR, Lees AJ, Evert BO, Klockgether T, Bonin M, et al. (2006) Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Exp Neurol 199: 465-478.
21. Zhang Y, James M, Middleton FA, Davis RL (2005) Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 137: 5-16.
22. Miller RM, Federoff HJ (2005) Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. Neuroscientist 11: 539-549.
23. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122(Pt 8): 1437-1448.
24. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114(Pt 5): 2283-2301.
25. Gibb WR (1991) Neuropathology of the substantia nigra. Eur Neurol 31 Suppl 1: 48-59.
26. Orr CF, Rowe DB, Halliday GM (2002) An inflammatory review of Parkinson's disease. Prog Neurobiol 68: 325-340.
27. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23: 474-483.
28. Lesnick TG, Papapetropoulos S, Mash DC, Ffrench-Mullen J, Shehadeh L, et al. (2007) A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 3: e98.
29. Dickson BJ (2002) Molecular mechanisms of axon guidance. Science 298: 1959-1964.
30. Croisier E, Graeber MB (2006) Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol 112: 517-530.
31. Mirza B, Hadberg H, Thomsen P, Moos T (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95: 425-432.
32. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, et al. (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14: 1709-1725.
33. Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, et al. (2001) Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci Lett 316: 129-132.
34. Cohen E, Dillin A (2008) The insulin paradox: aging, proteotoxicity and neurodegeneration. Nat Rev Neurosci 9: 759-767.
35. Sutherland G, Mellick G, Newman J, Double KL, Stevens J, et al. (2008) Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 147B: 495-499.
36. Barcia C, Bautista V, Sanchez-Bahillo A, Fernandez-Villalba E, Faucheux B, et al. (2005) Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm 112: 1237-1248.
37. Silverman WF, Krum JM, Mani N, Rosenstein JM (1999) Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures. Neuroscience 90: 1529-1541.
38. Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, et al. (2005) Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res 1053: 10-18.
39. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van Obberghen E (2000) Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 275: 21695-21702.
40. Beckert S, Farrahi F, Perveen Ghani Q, Aslam R, Scheuenstuhl H, et al. (2006) IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly (ADP-ribose) polymerase. Biochem Biophys Res Commun 341: 67-72.
41. Preece P, Cairns NJ (2003) Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. Brain Res Mol Brain Res 118: 60-71.
42. Preece P, Virley DJ, Costandi M, Coombes R, Moss SJ, et al. (2003) An optimistic view for quantifying mRNA in post-mortem human brain. Brain Res Mol Brain Res 116: 7-16.
43. Marcotte ER, Srivastava LK, Quirion R (2003) cDNA microarray and proteomic approaches in the study of brain diseases: focus on schizophrenia and Alzheimer's disease. Pharmacol Ther 100: 63-74.
44. Atz M, Walsh D, Cartagena P, Li J, Evans S, et al. (2007) Methodological considerations for gene expression profiling of human brain. J Neurosci Methods 163: 295-309.
45. Matigian NA, McCurdy RD, Feron F, Perry C, Smith H, et al. (2008) Fibroblast and lymphoblast gene expression profiles in schizophrenia: are non-neural cells informative? PLoS ONE 3: e2412.
46. McCurdy RD, Feron F, Perry C, Chant DC, McLean D, et al. (2006) Cell cycle alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I disorder using cell culture and gene expression analyses. Schizophr Res 82: 163-173.
47. Murrell W, Wetzig A, Donnellan M, Feron F, Burne T, et al. (2008) Olfactory Mucosa is a Potential Source for Autologous Stem Cell Therapy for Parkinson's Disease. Stem Cells.
48. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
49. Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R, et al. (2007) ArrayExpress-a public database of microarray experiments and gene expression profiles. Nucleic Acids Res 35: D747-750.
50. Hwang KB, Kong SW, Greenberg SA, Park PJ (2004) Combining gene expression data from different generations of oligonucleotide arrays. BMC Bioinformatics 5: 159.
51. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.